[1]
Turner GG, Nelson RR, Nordstrom LA, Diefenthal HC, Gobel FL. Comparative effect of nadolol and propranolol on exercise tolerance in patients with angina pectoris. British heart journal. 1978 Dec:40(12):1361-70
[PubMed PMID: 32899]
Level 2 (mid-level) evidence
[2]
Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, Flack JM, Carter BL, Materson BJ, Ram CV, Cohen DL, Cadet JC, Jean-Charles RR, Taler S, Kountz D, Townsend RR, Chalmers J, Ramirez AJ, Bakris GL, Wang J, Schutte AE, Bisognano JD, Touyz RM, Sica D, Harrap SB. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. Journal of clinical hypertension (Greenwich, Conn.). 2014 Jan:16(1):14-26. doi: 10.1111/jch.12237. Epub 2013 Dec 17
[PubMed PMID: 24341872]
Level 1 (high-level) evidence
[3]
Volicer L, Liang CS, Gavras H, Tifft CP, Kershaw GR, Gavras I, Griffith DL, Vukovitch R, Brunner HR. Effect of nadolol in treatment of hypertension. Journal of clinical pharmacology. 1979 Feb-Mar:19(2-3):137-47
[PubMed PMID: 33998]
[4]
January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW, ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014 Dec 2:130(23):e199-267. doi: 10.1161/CIR.0000000000000041. Epub 2014 Mar 28
[PubMed PMID: 24682347]
Level 1 (high-level) evidence
[5]
Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis AM, Granger CB, Hammill SC, Hlatky MA, Joglar JA, Kay GN, Matlock DD, Myerburg RJ, Page RL. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Journal of the American College of Cardiology. 2018 Oct 2:72(14):e91-e220. doi: 10.1016/j.jacc.2017.10.054. Epub 2018 Aug 16
[PubMed PMID: 29097296]
Level 1 (high-level) evidence
[6]
Pitzalis MV, Mastropasqua F, Massari F, Passantino A, Luzzi G, Forleo C, Rizzon P. Effects of nadolol and its combination with atrial pacing on rate-enhanced ventricular premature complexes. The American journal of cardiology. 1996 Nov 15:78(10):1177-9
[PubMed PMID: 8914889]
[7]
Pitzalis MV, Mastropasqua F, Massari F, Totaro P, Passantino A, Rizzon P. The effect of nadolol on heart rate and the standard deviation of the RR intervals. European heart journal. 1995 Feb:16(2):269-75
[PubMed PMID: 7744100]
[8]
Hayashi M, Denjoy I, Extramiana F, Maltret A, Buisson NR, Lupoglazoff JM, Klug D, Hayashi M, Takatsuki S, Villain E, Kamblock J, Messali A, Guicheney P, Lunardi J, Leenhardt A. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation. 2009 May 12:119(18):2426-34. doi: 10.1161/CIRCULATIONAHA.108.829267. Epub 2009 Apr 27
[PubMed PMID: 19398665]
[9]
Leren IS, Saberniak J, Majid E, Haland TF, Edvardsen T, Haugaa KH. Nadolol decreases the incidence and severity of ventricular arrhythmias during exercise stress testing compared with β1-selective β-blockers in patients with catecholaminergic polymorphic ventricular tachycardia. Heart rhythm. 2016 Feb:13(2):433-40. doi: 10.1016/j.hrthm.2015.09.029. Epub 2015 Sep 30
[PubMed PMID: 26432584]
[10]
Olukotun AY, Klein GJ. Efficacy and safety of intravenous nadolol for supraventricular tachycardia. The American journal of cardiology. 1987 Aug 31:60(6):59D-62D
[PubMed PMID: 3630923]
[11]
Chang MS, Sung RJ, Tai TY, Lin SL, Liu PH, Chiang BN. Nadolol and supraventricular tachycardia: an electrophysiologic study. Journal of the American College of Cardiology. 1983 Nov:2(5):894-903
[PubMed PMID: 6138376]
[12]
Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W, Practice Guidelines Committee of the American Association for the Study of Liver Diseases, Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology (Baltimore, Md.). 2007 Sep:46(3):922-38
[PubMed PMID: 17879356]
[13]
Hayes PC, Davis JM, Lewis JA, Bouchier IA. Meta-analysis of value of propranolol in prevention of variceal haemorrhage. Lancet (London, England). 1990 Jul 21:336(8708):153-6
[PubMed PMID: 1973480]
Level 1 (high-level) evidence
[14]
Merkel C, Marin R, Sacerdoti D, Donada C, Cavallarin G, Torboli P, Amodio P, Sebastianelli G, Bolognesi M, Felder M, Mazzaro C, Gatta A. Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Hepatology (Baltimore, Md.). 2000 Feb:31(2):324-9
[PubMed PMID: 10655253]
[15]
de la Peña J, Brullet E, Sanchez-Hernández E, Rivero M, Vergara M, Martin-Lorente JL, Garcia Suárez C. Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding: a multicenter trial. Hepatology (Baltimore, Md.). 2005 Mar:41(3):572-8
[PubMed PMID: 15726659]
Level 1 (high-level) evidence
[16]
Peden NR, Isles TE, Stevenson IH, Crooks J. Nadolol in thyrotoxicosis. British journal of clinical pharmacology. 1982 Jun:13(6):835-40
[PubMed PMID: 6124267]
[19]
Khilnani G, Khilnani AK. Inverse agonism and its therapeutic significance. Indian journal of pharmacology. 2011 Sep:43(5):492-501. doi: 10.4103/0253-7613.84947. Epub
[PubMed PMID: 22021988]
[20]
Hornung RS, Gould BA, Kieso H, Raftery EB. A study of nadolol to determine its effect on ambulatory blood pressure over 24 hours, and during exercise testing. British journal of clinical pharmacology. 1982 Jul:14(1):83-8
[PubMed PMID: 6125200]
[21]
Schäfer-Korting M, Bach N, Knauf H, Mutschler E. Pharmacokinetics of nadolol in healthy subjects. European journal of clinical pharmacology. 1984:26(1):125-7
[PubMed PMID: 6714285]
[22]
Tan HJ, Ling WC, Chua AL, Lee SK. Oral epigallocatechin gallate reduces intestinal nadolol absorption via modulation of Oatp1a5 and Oct1 transcriptional levels in spontaneously hypertensive rats. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2021 Sep:90():153623. doi: 10.1016/j.phymed.2021.153623. Epub 2021 Jun 11
[PubMed PMID: 34303263]
[23]
Heel RC, Brogden RN, Pakes GE, Speight TM, Avery GS. Nadolol: a review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris. Drugs. 1980 Jul:20(1):1-23
[PubMed PMID: 6105067]
[24]
Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2018 May 15:71(19):2199-2269. doi: 10.1016/j.jacc.2017.11.005. Epub 2017 Nov 13
[PubMed PMID: 29146533]
Level 3 (low-level) evidence
[25]
Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis AM, Granger CB, Hammill SC, Hlatky MA, Joglar JA, Kay GN, Matlock DD, Myerburg RJ, Page RL. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart rhythm. 2018 Oct:15(10):e190-e252. doi: 10.1016/j.hrthm.2017.10.035. Epub 2017 Oct 30
[PubMed PMID: 29097320]
Level 1 (high-level) evidence
[26]
Page RL, Joglar JA, Caldwell MA, Calkins H, Conti JB, Deal BJ, Estes NA 3rd, Field ME, Goldberger ZD, Hammill SC, Indik JH, Lindsay BD, Olshansky B, Russo AM, Shen WK, Tracy CM, Al-Khatib SM, Evidence Review Committee Chair‡. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2016 Apr 5:133(14):e471-505. doi: 10.1161/CIR.0000000000000310. Epub 2015 Sep 23
[PubMed PMID: 26399662]
Level 1 (high-level) evidence
[27]
Nademanee K, Schleman MM, Singh BN, Morganroth J, Reid PR, Stritar JA. Beta-adrenergic blockade by nadolol in control of ventricular tachyarrhythmias. American heart journal. 1984 Oct:108(4 Pt 2):1109-15
[PubMed PMID: 6207720]
[28]
Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology (Baltimore, Md.). 2017 Jan:65(1):310-335. doi: 10.1002/hep.28906. Epub 2016 Dec 1
[PubMed PMID: 27786365]
[29]
Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN, Walter MA. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid : official journal of the American Thyroid Association. 2016 Oct:26(10):1343-1421
[PubMed PMID: 27521067]
[30]
Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E, Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012 Apr 24:78(17):1337-45. doi: 10.1212/WNL.0b013e3182535d20. Epub
[PubMed PMID: 22529202]
Level 2 (mid-level) evidence
[31]
Herrera J, Vukovich RA, Griffith DL. Elimination of nadolol by patients with renal impairment. British journal of clinical pharmacology. 1979:7 Suppl 2(Suppl 2):227S-231S
[PubMed PMID: 37878]
[32]
Merkel C, Sacerdoti D, Finucci GF, Zuin R, Bazzerla G, Bolognesi M, Gatta A. Effect of nadolol on liver haemodynamics and function in patients with cirrhosis. British journal of clinical pharmacology. 1986 Jun:21(6):713-9
[PubMed PMID: 3741719]
[33]
. Nadolol (Corgard) - a new beta-blocker. The Medical letter on drugs and therapeutics. 1980 Apr 18:22(8):33-4
[PubMed PMID: 6102734]
Level 3 (low-level) evidence
[34]
Hitzenberger G. Initial experience with a new long-acting beta-blocker, nadolol, in hypertensive patients. The Journal of international medical research. 1979:7(1):33-8
[PubMed PMID: 33862]
[35]
Ehgartner GR, Zelinka MA. Hemodynamic instability following intentional nadolol overdose. Archives of internal medicine. 1988 Apr:148(4):801-2
[PubMed PMID: 3355299]
[36]
Burr DC, Ross J. How does binocular delay give information about depth? Vision research. 1979:19(5):523-32
[PubMed PMID: 483580]